Benitec: 100% responder rate in OPMD Gene Therapy Study
Benitec Biopharma announced 100% responder rates for high and low dose BB-301; interim high dose results showed superior improvements in swallowing function needed to advance towards a pivotal trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed